Durability of Sustained Virologic Response in Chronic Hepatitis C

Basit Öğe Kaydı
dc.contributor.authorUyanıkoğlu, Ahmet
dc.contributor.authorKaymakoğlu, Sabahattin
dc.contributor.authorDanalıoğlu, Ahmet
dc.contributor.authorAkyüz, Filiz
dc.contributor.authorErmiş, Fatih
dc.contributor.authorPınarbaşı, Binnur
dc.contributor.authorÇakaloğlu, Yılmaz
dc.date.accessioned2020-05-01T09:11:31Z
dc.date.available2020-05-01T09:11:31Z
dc.date.issued2013
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionUyanikoglu, Ahmet/0000-0003-4881-5244en_US
dc.descriptionWOS: 000322057500012en_US
dc.descriptionPubMed: 23898387en_US
dc.description.abstractBackground/Aims: The aim of this study is to investigate the rate of sustained virologic response (SVR) in chronic hepatitis C patients receiving antiviral treatment. Methods: The files of patients with chronic hepatitis C treated with interferon ribavirin between 1995 and 2009 were reviewed retrospectively. Six months after the end of treatment, patients with negative hepatitis C virus (HCV)-RNA (<50 IU/mL, as determined by the polymerase chain reaction method) were enrolled in the study. Results: The mean age of 196 patients (89 males) was 46.13 +/- 11.10 years (range, 17 to 73 years). In biopsies, the mean stage was 1.50 +/- 0.94; histological activity index was 7.18 +/- 2.43. In total, 139 patients received pegylated interferon (IFN)+ribavirin, 21 patients received classical IFN+ribavirin, and 36 patients received IFN alone. The HCV genotypes of 138 patients were checked: 77.5% were genotype 1b, and 22.5% were other genotypes. After achievement of SVR, the median follow-up period was 33.5 months (range, 6 to 112 months), and in this period relapse was only detected in two patients (1.02%) at 18 and 48 months after treatment. Conclusions: In total, 98.9% of patients with SVR in chronic hepatitis C demonstrated truly durable responses over the long-term follow-up period of 3 years; relapsed patients had intermittent or low-grade viremia.en_US
dc.identifier.doi10.5009/gnl.2013.7.4.458en_US
dc.identifier.endpage461en_US
dc.identifier.issn1976-2283
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage458en_US
dc.identifier.urihttps://doi.org/10.5009/gnl.2013.7.4.458
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5640
dc.identifier.volume7en_US
dc.identifier.wosWOS:000322057500012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherEditorial Office Gut & Liveren_US
dc.relation.ispartofGut And Liveren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectInterferonsen_US
dc.titleDurability of Sustained Virologic Response in Chronic Hepatitis Cen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5640.pdf
Boyut:
185.61 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize